NCT05451628

Brief Summary

Severe to profound hearing loss affects 0,8% of the global population. For these people, a conventional hearing aid often does not provide sufficient benefit. However, these people can benefit from a cochlear implant (CI). A CI needs to be individually programmed (fitted) for each recipient. A fitting "map" is defined as a set of electrical parameters that are individually adapted to a recipient's needs to achieve optimal sound perception. At present, most CI recipients are fitted with a default frequency allocation map that doesn't take individual variability in size and shape of the cochlea into account. In this study, a fitting strategy based on the post-operative CT scan, that will allow the audiologist to set a frequency-band distribution for CI fitting that may be more closely aligned to the natural tonotopic frequency distribution of a normal hearing cochlea, will be evaluated.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 30, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 2, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 11, 2022

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2025

Completed
Last Updated

December 12, 2023

Status Verified

December 1, 2023

Enrollment Period

2.8 years

First QC Date

June 2, 2022

Last Update Submit

December 11, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • Speech recognition test in quiet (S0): percentage correctly identified phonemes

    3 months post-activation

  • Speech recognition test in quiet (S0): percentage correctly identified phonemes

    6 months post-activation

Secondary Outcomes (17)

  • Speech recognition test in noise (S0N0): the speech reception threshold in dB SNR

    3 months post-activation

  • Speech recognition test in noise (S0N0): the speech reception threshold in dB SNR

    6 months post-activation

  • Result of the pitch matching test: frequency difference in semitones

    3 months post-activation

  • Result of the pitch matching test: frequency differences in semitones

    6 months post-activation

  • Result of the perception of timbre test: Score on Visual Analog Scale (VAS)

    3 months post-activation

  • +12 more secondary outcomes

Study Arms (2)

Default CI fitting

ACTIVE COMPARATOR

Programming of cochlear implant speech processor according to standard clinical care

Device: Default CI fitting

Anatomy-based CI fitting

ACTIVE COMPARATOR

Programming of cochlear implant speech processor with anatomy-based fitting

Device: Anatomy-based CI fitting

Interventions

Programming of cochlear implant speech processor according to standard clinical care

Default CI fitting

Programming of cochlear implant speech processor with anatomy-based fitting

Anatomy-based CI fitting

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years
  • Post-lingual onset of severe to profound sensory-neural hearing loss in the implanted ear(s)
  • Post-operative Computed Tomography (CT) scan of the CI electrode available
  • Pre-operative result of pure-tone audiometry, speech test in quiet and in noise available
  • Subject implanted with MED-EL cochlear implant(s)
  • Subjects received a Flex28, FlexSoft or Standard electrode
  • Subject planned to receive a SONNET 2 or RONDO 3 audio processor on the newly implanted side
  • Audio processor not yet activated on the newly implanted side
  • The most apical active electrode contact has to be inserted at least 450°
  • Minimum of 10 active channels can be activated
  • Fluent in the language of the test centre
  • Signed and dated Informed Consent Form (ICF) before the start of any study-specific procedure

You may not qualify if:

  • Electric Acoustic Stimulation (EAS) user (user of an EAS audio processor)
  • Implanted with C40+, C40X and C40C
  • Implanted with an Auditory Brainstem Implant (ABI) or Split electrode array
  • Anything that, in the opinion of the Investigator, would place the subject at increased risk or pre-clude the subject's full compliance with or completion of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UZ Brussel

Brussels, 1090, Belgium

RECRUITING

MeSH Terms

Conditions

Hearing Loss, Sensorineural

Condition Hierarchy (Ancestors)

Hearing LossHearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Vedat Topsakal, Prof.

    UZB-VUB

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 2, 2022

First Posted

July 11, 2022

Study Start

March 30, 2022

Primary Completion

January 1, 2025

Study Completion

January 1, 2025

Last Updated

December 12, 2023

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

Locations